STOCK TITAN

If You Invested in Natural Alternatives International Inc. (NAII)

Consumer Defensive · Packaged Foods · NASDAQ
Looking for the current price? See the NAII quote & overview
$1,000 invested 1 Year Ago
$238
-76.2% price return
-76.2% with dividends reinvested
Bought on Nov 24, 2025 at $3.68 split-adjusted
$1,000 invested 5 Years Ago
$66
-93.4% price return -41.9% CAGR
-93.4% with dividends reinvested
Bought on Nov 22, 2021 at $13.18 split-adjusted

What $1,000 or $10,000 in NAII Would Be Worth Now

Real historical value by amount invested and how long ago
If you invested 1 year ago 5 years ago 10 years ago Since Nov 23, 2015
$1,000 $238 -76% $66 -93% $66 -93% $122 -88%
$10,000 $2,380 -76% $665 -93% $661 -93% $1,217 -88%

Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-20. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.

Custom Calculation

Choose your own date and amount for NAII

$1,000 Investment Over Time

NAII vs S&P 500

Year-by-Year Returns

NAII annual performance
Year Start Price End Price Annual Return Cumulative
2015Nov 23 to Dec 31 $7.20 $10.34 +43.6% +43.6%
2016 $10.34 $11.30 +9.3% +56.9%
2017 $11.30 $10.30 -8.8% +43.1%
2018 $10.30 $9.83 -4.6% +36.5%
2019 $9.83 $7.98 -18.8% +10.8%
2020 $7.98 $10.59 +32.7% +47.1%
2021 $10.59 $12.65 +19.5% +75.7%
2022 $12.65 $8.39 -33.7% +16.5%
2023 $8.39 $6.53 -22.2% -9.3%
2024 $6.53 $4.31 -34.0% -40.1%
2025 $4.31 $3.58 -16.9% -50.3%
2026Dec 31, 2025 to Nov 20 $3.58 $0.8760 -75.5% -87.8%

About Natural Alternatives International Inc.

Consumer Defensive · NASDAQ

Natural Alternatives International, Inc. (NASDAQ: NAII) is a formulator, manufacturer, and marketer of customized nutritional supplements. According to company disclosures, NAI is headquartered in Carlsbad, California and operates in the medicinal and botanical manufacturing space within the broader manufacturing sector. The company serves customers in the United States and internationally and is engaged in both private-label contract manufacturing and patent and trademark licensing activities related to nutritional and healthcare products.

NAI’s core operations include formulating, manufacturing, and marketing nutritional supplements. Based on its public descriptions, the company offers vitamins, minerals, herbs, and other nutritional supplements, as well as other healthcare products, to customers that market and distribute these products under their own brands. The Private-Label Contract Manufacturing segment provides manufacturing services to companies that sell nutritional supplements and related healthcare products, while the Patent & Trademark Licensing segment generates royalty income from license and supply agreements associated with the sale of branded ingredients.

Business Segments and Revenue Drivers

NAI reports that it operates through two main business segments: Private-Label Contract Manufacturing and Patent & Trademark Licensing. The company states that it derives the majority of its revenue from private-label contract manufacturing, where it manufactures nutritional supplements and other healthcare products for third-party brand owners. These customers then market and distribute the finished products to consumers in various markets.

The Patent & Trademark Licensing segment is associated with NAI’s branded ingredient business, primarily centered on CarnoSyn® beta-alanine and related products. NAI receives royalty, licensing, and raw material sales revenue from license and supply agreements tied to CarnoSyn® beta-alanine and its derivatives. Company press releases also highlight the development and commercialization of TriBsyn™, described as a carnosine booster derived from CarnoSyn® beta-alanine and formulated using proprietary technology.

CarnoSyn® Brands and TriBsyn™

NAI reports that CarnoSyn® Brands feature three clinically studied, patented and patent-pending ingredients available exclusively from the company: CarnoSyn® instant release beta-alanine powder, SR CarnoSyn® sustained release beta-alanine tablets, and TriBsyn™ powder. Public disclosures state that TriBsyn™ is a patent-pending formula that utilizes proprietary technology to increase beta-alanine bioavailability and absorption while effectively eliminating the common paresthesia sensation associated with efficacious dosages of beta-alanine.

In a published clinical study summarized by NAI and CarnoSyn® Brands, TriBsyn™ is described as an encapsulated low-dose beta-alanine complex that increased plasma beta-alanine concentrations compared to conventional beta-alanine, with reported elimination of paresthesia in the study group receiving TriBsyn™. NAI indicates that TriBsyn™ is positioned as a carnosine booster with applications in dietary supplements, medical foods, and other fortified food products, with a focus on areas such as muscle vitality, cognitive performance, and healthy aging.

Strategic Partnering and Service Offering

Across multiple press releases, NAI describes itself as providing strategic partnering services to its customers. The company states that its partnership approach offers a range of nutritional products and services to clients, including:

  • Scientific research and, in some disclosures, clinical studies
  • Proprietary ingredients, including CarnoSyn® beta-alanine and TriBsyn™
  • Customer-specific nutritional product formulation
  • Product testing and evaluation
  • Marketing management and support
  • Packaging and delivery system design
  • Regulatory review
  • International product registration assistance

These services are presented by NAI as part of its integrated offering to brand-owner customers that seek support from formulation through manufacturing and regulatory processes.

Customer Relationships and Manufacturing Agreements

NAI’s disclosures highlight long-term relationships with key customers. For example, the company reports a multi-decade relationship with The Juice Plus+ Company, described as a globally recognized provider of plant-based whole-body nutritional products. In an 8-K filing and corresponding press release, NAI announced a new multi-year Manufacturing Agreement with Juice Plus+ covering capsule and powder products sold in over 24 markets. The agreement sets forth terms for NAI to manufacture and supply Juice Plus+ products within 24 countries, with an initial term ending July 16, 2027.

NAI also notes that growth in its private-label contract manufacturing sales has been driven at various times by increased orders from existing customers and shipments to new customers. Company commentary in earnings releases references efforts to expand client relationships, diversify channels, and support new product launches that incorporate NAI’s proprietary ingredients.

Financial Reporting and Exchange Listing

Natural Alternatives International, Inc. is incorporated in Delaware and, according to its SEC filings, its common stock trades on the NASDAQ under the symbol NAII. The company files periodic financial statements and current reports with the U.S. Securities and Exchange Commission, including Form 10-K annual reports, Form 10-Q quarterly reports, and Form 8-K current reports describing material events such as credit facility amendments, manufacturing agreements, and shareholder meeting results.

Recent earnings press releases describe NAI’s financial performance in terms of net sales, segment contributions from private-label contract manufacturing and CarnoSyn® beta-alanine royalty, licensing and raw material sales, and factors affecting profitability such as factory capacity utilization, sales mix, manufacturing costs, and legal and administrative expenses. The company also reports on its cash position, working capital, borrowing capacity under its credit facility, and balance sheet metrics.

Capital Structure and Credit Facility

NAI’s SEC filings indicate that the company maintains a credit facility with Wells Fargo Bank, National Association. In a June 2025 8-K filing, NAI reported entering into an amended credit facility that extended the term of its existing credit agreement to December 31, 2026 and adjusted the maximum principal amount available under the revolving line of credit. The filing notes that the company’s powder processing facility in Carlsbad, California was added as security for the amended credit agreement, and that related agreements such as the credit agreement amendments, revolving line of credit note modification, and deed of trust modification were executed.

In a December 2025 8-K filing, NAI disclosed that for its fiscal first quarter ended September 30, 2025, it was not in compliance with certain financial covenants under the credit agreement, specifically maximum net loss and fixed charge coverage ratio covenants. The company reported entering into a Waiver and Release Agreement with Wells Fargo under which the bank waived all related defaults and confirmed that the credit agreement and related agreements remained in full force and effect.

Corporate Governance and Shareholder Matters

NAI’s proxy statement and related 8-K filings describe its corporate governance and shareholder voting processes. The company holds an Annual Meeting of Stockholders, which, according to recent proxy materials, is conducted as an online meeting via live webcast. Shareholders of record as of a specified record date are entitled to vote on matters such as the election of directors, amendments to equity incentive plans, ratification of the independent registered public accounting firm, advisory votes on executive compensation, and the frequency of such advisory votes.

A December 2025 8-K filing summarizing the results of the annual meeting reports that shareholders voted on the election of a Class II director, approval of the First Amendment to the 2020 Omnibus Equity Incentive Plan, ratification of the company’s independent registered public accounting firm, advisory approval of named executive officer compensation, and the advisory frequency of future compensation votes. The filing indicates that these proposals were approved, with shareholders supporting a three-year frequency for advisory votes on executive compensation.

Research, Clinical Evidence, and Industry Positioning

NAI emphasizes scientific support for its proprietary ingredients. In collaboration with CarnoSyn® Brands, the company announced the publication of a clinical trial in the journal Food Hydrocolloids for Health evaluating TriBsyn™. The study, as described in NAI’s public communication, was a randomized, double-blind, single-dose, three-treatment, three-way crossover oral bioavailability study in healthy older adults under fasting conditions. The trial compared TriBsyn™ with low and high doses of conventional beta-alanine and reported increased plasma beta-alanine concentrations and reduced sensory side effects for TriBsyn™.

NAI and CarnoSyn® Brands also participate in scientific and industry conferences. For example, they reported exhibiting at the ESPEN Congress on Clinical Nutrition & Metabolism and the European Geriatric Medicine Society Congress to discuss clinical evidence related to TriBsyn™ and to engage with professionals in clinical nutrition and geriatric medicine.

Stock Classification and Investor Considerations

Natural Alternatives International, Inc. is a publicly traded company in the manufacturing sector, focused on nutritional supplements and related patented ingredients. It is not described in the provided materials as part of a major large-cap index such as the S&P 500. Investors researching NAII stock can review the company’s SEC filings, earnings press releases, and other public disclosures to understand its segment performance, customer relationships, proprietary ingredient portfolio, and capital structure.

Market Cap
$5.5M
Current Price
$0.8760
EPS (FY2026)
-$3.43
Revenue (FY2026)
$142.5M
Net Margin (FY2026)
-14.5%
View full NAII overview

Frequently Asked Questions

Natural Alternatives International Inc. investment returns

How much would $1,000 invested in Natural Alternatives International Inc. be worth today?

If you invested $1,000 in Natural Alternatives International Inc. (NAII) 10 years ago on 2016-11-22, your investment would be worth $66 as of 2026-11-20, a -93.4% price return without dividends, growing at a compounded rate of -23.8% per year (CAGR).

Has Natural Alternatives International Inc. outperformed the S&P 500?

Over the past 10 years, NAII returned -93.4% compared to +212.7% for the S&P 500, underperforming the benchmark by 306.1 percentage points.

What is Natural Alternatives International Inc.'s average annual return?

The compound annual growth rate (CAGR) of NAII’s share price over the past 10 years is -23.8%, without dividends. Individual years vary a great deal, and NAII’s best recent full year was 2020 (+32.7%) while the worst was 2024 (-34.0%).

For informational and educational purposes only, not investment advice.